“Philanthropy won’t scale precision medicine. Partnership will.”
Transformative health innovation requires aligned investment strategies, clear governance models, and long-term commitment across sectors. In an era where public health challenges are global and complex, siloed funding and disconnected innovation cycles are no longer sustainable.
This session examines successful public–private partnership models that deliver scalable and accountable outcomes. Drawing from flagship EU-funded initiatives such as BRECISE, SPARC, GenoMed4All, and the Joint Action on Cancer and Personalised Medicine, we will explore how these collaborations are delivering infrastructure for molecular diagnostics, data-sharing platforms, and training ecosystems that serve both public health and industrial competitiveness.
The session will review principles of good governance, such as transparency, open data standards, outcomes-based funding, and patient involvement in project design and monitoring. Special focus will be given to how PPPs can support the goals of the EU Cancer Mission and align with national implementation efforts, ensuring that innovation pipelines are de-risked and value is measured in societal as well as economic terms.
EAPM has consistently emphasised the role of collaborative ecosystems in achieving scale in personalised medicine. By facilitating dialogue between policymakers, clinicians, industry, and patient groups, the Alliance has helped shape models that translate cutting-edge research into system-level impact.
Conclusion:Strategic, mission-driven PPPs are essential to scale precision health tools across Europe. The next generation of partnerships must be grounded in public value, co-designed with end-users, and built to deliver sustainable innovation.
